Document Detail


Early intervention: which patients and how early?
MedLine Citation:
PMID:  18611365     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Despite advances in preventive therapy, acute coronary syndromes (ACS) remain a significant cause of morbidity and mortality. Patient risk varies widely along a spectrum from unstable angina to ST-segment elevation myocardial infarctions (STEMIs) and can be estimated using risk prediction algorithms. Estimated risk is useful to select therapeutic options ranging from aggressive medical therapy for patients at low risk to revascularization for high-risk patients in whom bypass or percutaneous coronary intervention (PCI) is feasible. Appropriate timing of an invasive strategy is crucial, with early intervention maximally benefiting the highest-risk patients. Facilitated PCI's role in patients who present with STEMI and the most appropriate timing of interventional therapy in patients at moderate risk after a non-ST-elevation ACS remain the subject of ongoing debate.
Authors:
J Matthew Brennan; John L Petersen
Related Documents :
17721625 - Evaluation of antibodies to oxidized low-density lipoprotein and assessment of c-reacti...
15778205 - The clinical characteristics and investigations planned in patients with stable angina ...
20674205 - Coronary dual source multi detector computed tomography in patients suspected of corona...
2328165 - Identification of a high risk subgroup of patients with silent ischaemia after myocardi...
6770625 - Reduction of venous thrombosis complicating phlebography.
23869655 - Effect of intravenous lipid emulsion in patients with acute glyphosate intoxication.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current cardiology reports     Volume:  10     ISSN:  1534-3170     ISO Abbreviation:  Curr Cardiol Rep     Publication Date:  2008 Jul 
Date Detail:
Created Date:  2008-07-09     Completed Date:  2008-10-24     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100888969     Medline TA:  Curr Cardiol Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  303-11     Citation Subset:  IM    
Affiliation:
Division of Cardiovascular Medicine, Duke University Medical Center, Durham, NC 27705, USA. brenn009@mc.duke.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Coronary Syndrome / drug therapy,  physiopathology,  surgery,  therapy*
Algorithms
Angioplasty, Transluminal, Percutaneous Coronary*
Coronary Artery Bypass*
Fibrinolytic Agents / therapeutic use
Humans
Myocardial Revascularization
Platelet Aggregation Inhibitors / therapeutic use
Predictive Value of Tests
Risk Assessment
Risk Factors
Time Factors
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; 0/Platelet Aggregation Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  New data on early management of patients with ST-elevation myocardial infarction.
Next Document:  Which heparin and how much?